ebook Munafa Stock Market Course + Intraday & FNO calls  

       

NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

Novo Nordisk A/s Complete list of announcements declared & dividend announcements by Novo Nordisk A/s NVO

Novo Nordisk A/s NVO listed on NYSE and deals in Health Care Major Pharmaceuticals

Announcements and dividends declared by Novo Nordisk A/s NVO

Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expires
Natco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the innovator's drug. The company aims to make this treatment more accessible to patients across India. Other pharmaceutical
Announcement as on 20 March 2026

FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Announcement as on 20 March 2026

Novo Nordisk says new weight-loss drug not as potent as Eli Lilly's; stock sinks

Announcement as on 23 February 2026

Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expiry
Sun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GLP-1 receptor agonist will be available after patent expiry, offering a crucial treatment option for India's growing o
Announcement as on 23 January 2026

Veeva Expands Partnership With Novo Nordisk Through Vault CRM Adoption
(RTTNews) - Veeva Systems Inc. (VEEV), a cloud software company, on Wednesday said Novo Nordisk's International Operations business unit has committed to use Veeva Vault CRM, expanding the companies' existing partnership.
Announcement as on 07 January 2026

Announcements by Novo Nordisk A/s first page | Next page |

NVO Novo Nordisk A/s current price & indicator signals

Moving Averages for Novo Nordisk A/s

  • 5Day Average: 37.72
  • 12Day Average: 38.35
  • 20Day Average: 38.67
  • 50Day Average: 48.55
  • 100Day Average: 48.98
  • 150Day Average: 51.37
  • 200Day Average: 55.17

NVO Indicators & signals

Indicator MACD (12,26,9)

38.44, 41.25, -3.17
Indicator MACD is in negative zone

Indicator ADX (14)

40.66, 16.36, 38.79
Indicator ADX is indicating that momentum is weak.
Momentum is towards selling.

Indicator RSI (14)

Current RSI is: 52
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of NVO Novo Nordisk A/s are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
20 Fri Mar 2026 36.54 35.86 to 37.33 -1.43% 1.42 times
19 Thu Mar 2026 37.07 36.17 to 37.47 -3.56% 1.13 times
17 Tue Mar 2026 38.44 38.30 to 39.27 -0.36% 0.65 times
16 Mon Mar 2026 38.58 37.79 to 38.59 1.63% 0.74 times
13 Fri Mar 2026 37.96 37.70 to 38.80 -0.16% 0.74 times
12 Thu Mar 2026 38.02 37.85 to 39.02 -2.14% 1.1 times
11 Wed Mar 2026 38.85 38.36 to 39.13 0.34% 0.66 times
10 Tue Mar 2026 38.72 38.18 to 39.22 -2.76% 1.34 times
09 Mon Mar 2026 39.82 37.68 to 39.88 3.21% 1.26 times
06 Fri Mar 2026 38.58 38.17 to 38.85 -1.25% 0.99 times
05 Thu Mar 2026 39.07 38.08 to 39.12 1.48% 1.39 times
04 Wed Mar 2026 38.50 37.29 to 38.60 5.02% 1.73 times

Videos related to: NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

Hindi Video Most Important Stock Market Video. No Success Without This Formula

Hindi Video What Is Needed To Succeed In Stock Markets

NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE

 

Back to top